Vertex Stuck Between A Good Place And A Better Place
Two three-drug regimens for cystic fibrosis hit their primary endpoints in both heterozygous and homozygous patients, with good safety and tolerability, which analysts say increases the likelihood one of them will obtain approval.
You may also be interested in...
Already dominant in cystic fibrosis, Vertex hopes its triple regimen will address roughly 90% of the patient population. It also hopes the benefits of the triple will smooth EU reimbursement talks.
With data showing a lung function and sweat chloride benefit for its proprietary CFTR-modulating triplet, Proteostasis says it’s moving ahead. But analysts and investors are concerned the effects are less than seen with Vertex drugs.